

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **VOLUNTARY ANNOUNCEMENT UNAUDITED OPERATING STATISTICS FOR THE PERIOD FROM JANUARY 1, 2025 TO JUNE 30, 2025**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the six months ended June 30, 2025 (the “**Reporting Period**”), and the comparative figures as set out below.

	<b>For the period from</b>		
	<b>January 1 to June 30</b>		
	<b>2025</b>	<b>2024</b>	<b>Change</b>
	<b>RMB'million</b>	<b>RMB'million</b>	<b>%</b>
	<b>Approximately</b>		<b>Approximately</b>
Revenue	<b>350.0–360.0</b>	301.2	<b>16.2–19.5</b>

The Group’s sustained revenue growth was primarily driven by the following factors:

- (i) further market share gains in China’s transcatheter aortic valve replacement (“**TAVR**”) market as well as product mix shifting to newly launched premium products; and

- (ii) robust performance of key neurointerventional products, exemplified by:
- a. deepening market penetration of the existing advantageous products including DCwire<sup>®</sup> Micro Guidewire, Tethys AS<sup>®</sup> Aspiration Catheter and Fastunnel<sup>®</sup> Delivery Balloon Dilatation Catheter; and
  - b. successful launch of the newly approved YonFlow<sup>®</sup> Flow Diverting Stent.

During the Reporting Period, the Group's comprehensive TAVR portfolio — comprising TaurusOne<sup>®</sup>, TaurusElite<sup>®</sup> and newly launched TaurusMax<sup>®</sup> — expanded into over 70 new hospitals, bringing cumulative coverage to over 720 hospitals as of June 30, 2025. Total TAVR implantations exceeded 2,050 units for the Reporting Period, representing a period-to-period growth of approximately 18.8%.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the interim results of the Group for the Reporting Period. The above operating information is preliminary unaudited information that has not been reviewed, confirmed or audited by the auditors of the Company, nor reviewed by the audit committee of the Board, and is provided for investors reference only and it shall not be taken as a measure or indication of the Group's future financial performance. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the Reporting Period, which is expected to be published in August 2025 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, August 6, 2025

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.*